Roswell Park study: Targeting HSP60-ClpP axis may improve outcomes in prostate cancer

HIFU demonstrates positive outcomes in management of prostate cancer, study shows

EDAP TMS SA, the global leader in robotic energy-based therapies, announced the publication of the full results from the HIFI study in European Urology, which has the highest impact factor amongst scientific journals focused in urology. The study evaluated high-intensity focused ultrasound versus radical prostatectomy as a first line treatment of localized prostate cancer.

December 13, 2024

Vol.50 No.46

Clinical Roundup

Blood test predicts prognosis for advanced prostate cancer, study finds

A new study, published in Nature Communications and led by the University of Minnesota Medical School and Duke University, found that a DNA sequencing test for advanced prostate cancer patients can distinguish between patients with poor and favorable prognoses. The new blood-based test — called AR-ctDETECT — is designed to detect and analyze small fragments of tumor-derived DNA in the blood of certain patients with advanced, metastatic prostate cancer.

December 13, 2024

Vol.50 No.46

In Brief

Michael Wong joins Roswell Park as physician-in-chief

Michael Wong joined Roswell Park Comprehensive Cancer Center as the center’s first physician-in-chief.

December 06, 2024

Vol.50 No.45

In Brief

TD Bank recommits $100K to MUSC Hollings’s SC AMEN program

TD Bank has committed $100,000 to support the MUSC Hollings Cancer Center’s SC AMEN program, a community outreach initiative that brings education, screenings, and health services assistance to Black men 40 to 69 years old in South Carolina.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Mushroom supplement may slow prostate cancer progression, City of Hope study finds

Researchers at City of Hope found that taking white button mushroom pills reduces a class of immune cells called myeloid-derived suppressor cells, which has been linked to cancer development and spread.

November 22, 2024

Vol.50 No.44

Clinical Roundup

Hemokine modulatory regimen shows promise for TNBC in phase I study

A new treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase I clinical trial for patients with triple-negative breast cancer, the most aggressive type of breast cancer. Results of the study are newly reported in The Journal for ImmunoTherapy of Cancer.

November 22, 2024

Vol.50 No.44

Roswell Park study: Targeting HSP60-ClpP axis may improve outcomes in prostate cancer

YOU MAY BE INTERESTED IN

HIFU demonstrates positive outcomes in management of prostate cancer, study shows

Blood test predicts prognosis for advanced prostate cancer, study finds

Michael Wong joins Roswell Park as physician-in-chief

TD Bank recommits $100K to MUSC Hollings’s SC AMEN program

Mushroom supplement may slow prostate cancer progression, City of Hope study finds

Hemokine modulatory regimen shows promise for TNBC in phase I study

Renew today!

Subscriber content

Never miss an issue!

Login